{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:51:07Z","timestamp":1791924667473,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11906-019-1001-4","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:01:40Z","timestamp":1574060500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Arterial Hypertension, Aldosterone, and Atrial Fibrillation"],"prefix":"10.1007","volume":"21","author":[{"given":"Teresa M.","family":"Seccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brasilina","family":"Caroccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"1001_CR1","first-page":"1029","volume":"39","author":"TM Seccia","year":"2018","unstructured":"\u2022\u2022 Seccia TM, Caroccia B, Gomez-Sanchez EP, Gomez-Sanchez CE, Rossi GP. The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications. Endocr Rev. 2018;39:1029\u201356. This review examines pathophysiology of aldosterone synthesis and deleterious effects of excess aldosterone levels.","journal-title":"Endocr Rev"},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","volume":"19","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88\u201390.","journal-title":"Trends Endocrinol Metab"},{"issue":"7","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2008-0251","volume":"93","author":"Gian Paolo Rossi","year":"2008","unstructured":"Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93:2566\u201371.","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2016.01.007","volume":"206","author":"TM Seccia","year":"2016","unstructured":"Seccia TM, Caroccia B, Muiesan ML, Rossi GP. Atrial fibrillation and arterial hypertension: a common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. Int J Cardiol. 2016;206:71\u20136.","journal-title":"Int J Cardiol"},{"key":"1001_CR5","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/01.HYP.24.5.585","volume":"24","author":"WS Post","year":"1994","unstructured":"Post WS, Larson MG, Levy D. Hemodynamic predictors of incident hypertension. The Framingham Heart Study. Hypertension. 1994;24:585\u201390.","journal-title":"Hypertension"},{"key":"1001_CR7","doi-asserted-by":"publisher","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N\u20139N.","journal-title":"Am J Cardiol"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293\u2013300.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"Silvia Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811\u201320.","journal-title":"Journal of the American College of Cardiology"},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408360600931831","volume":"44","author":"GP Rossi","year":"2007","unstructured":"Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci. 2007;44:1\u201385.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1001_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1161\/HYPERTENSIONAHA.117.09991","volume":"70","author":"TM Seccia","year":"2017","unstructured":"Seccia TM, Caroccia B, Gomez-Sanchez EP, Vanderriele PE, Gomez-Sanchez CE, Rossi GP. Review of markers of zona glomerulosa and aldosterone-producing adenoma cells. Hypertension. 2017;70:867\u201374.","journal-title":"Hypertension"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1469-7793.2001.0151k.x","volume":"537","author":"JP B\u00e9nitah","year":"2001","unstructured":"B\u00e9nitah JP, Perrier E, G\u00f3mez AM, Vassort G. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol. 2001;537:151\u201360.","journal-title":"J Physiol"},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.108.805804","volume":"119","author":"AM G\u00f3mez","year":"2009","unstructured":"G\u00f3mez AM, Rueda A, Sainte-Marie Y, Pereira L, Zissimopoulos S, Zhu X, et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009;119:2179\u201387.","journal-title":"Circulation"},{"issue":"23","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"Antoine Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud A, Sainte-Marie Y, B\u00e9nitah J-P, Perrier R, Soukaseum C, Nguyen Dinh Cat A, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025\u201333.","journal-title":"Circulation"},{"key":"1001_CR15","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","volume":"33","author":"J-CC Reil","year":"2012","unstructured":"\u2022\u2022 Reil J-CC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. Eur Heart J. 2012;33:2098\u2013108. This study first provided in vivo evidence that aldosterone can cause atrial fibrillation. Seccia.","journal-title":"Eur Heart J"},{"issue":"5-6","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1159\/000178483","volume":"29","author":"Carina Lammers","year":"2012","unstructured":"Lammers C, Dartsch T, Brandt MC, Rottl\u00e4nder D, Halbach M, Peinkofer G, et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol Biochem. 2012;29:833\u201340.","journal-title":"Cellular Physiology and Biochemistry"},{"issue":"5","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"Gian Paolo Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039\u201345.","journal-title":"Hypertension"},{"key":"1001_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.108.111369","volume":"51","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366\u201371.","journal-title":"Hypertension"},{"issue":"7","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1097\/00004872-200207000-00032","volume":"20","author":"Maria Lorenza Muiesan","year":"2002","unstructured":"Muiesan ML, Rizzoni D, Salvetti M, Porteri E, Monteduro C, Guelfi D, et al. Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens. 2002;20:1439\u201344.","journal-title":"Journal of Hypertension"},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","volume":"55","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55:1137\u201342.","journal-title":"Hypertension"},{"key":"1001_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","volume":"40","author":"GP Rossi","year":"2002","unstructured":"Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23\u20137.","journal-title":"Hypertension"},{"issue":"10","key":"1001_CR22","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"Ricardo Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871\u20138.","journal-title":"Endocrinology"},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCRESAHA.116.305381","volume":"116","author":"A Leask","year":"2015","unstructured":"Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ Res. 2015;116:1269\u201376.","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"1001_CR24","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1038\/sj.jhh.1000747","volume":"13","author":"T Yamazaki","year":"1999","unstructured":"Yamazaki T, Yazaki Y. Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress. J Hum Hypertens. 1999;13(Suppl 1):S43\u20137.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"Ricardo Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802\u201310.","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773\u201381.","journal-title":"Am J Pathol"},{"key":"1001_CR27","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCRESAHA.114.302226","volume":"114","author":"J Heijman","year":"2014","unstructured":"\u2022\u2022 Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114:1483\u201399. This comprehensive review examines the molecular mechanisms underlying development and persistence of atrial fibrillation.","journal-title":"Circ Res"},{"issue":"4","key":"1001_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00380-006-0968-3","volume":"22","author":"Kyoe Tanaka","year":"2007","unstructured":"Tanaka K, Ashizawa N, Kawano H, Sato O, Seto S, Nishihara E, et al. Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts. Heart Vessel. 2007;22:254\u201360.","journal-title":"Heart and Vessels"},{"key":"1001_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2013.06.046","volume":"169","author":"C-F Tsai","year":"2013","unstructured":"Tsai C-F, Yang S-F, Chu H-J, Ueng K-C. Cross-talk between mineralocorticoid receptor\/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol. 2013;169:17\u201328.","journal-title":"Int J Cardiol"},{"key":"1001_CR30","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","volume":"289","author":"D Lavall","year":"2014","unstructured":"Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Sch\u00e4fers H-J, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289:6656\u201368.","journal-title":"J Biol Chem"},{"key":"1001_CR31","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.jacc.2017.10.014","volume":"70","author":"Y Takemoto","year":"2017","unstructured":"Takemoto Y, Ramirez RJ, Kaur K, Salvador-Monta\u00f1\u00e9s O, Ponce-Balbuena D, Ramos-Mondrag\u00f3n R, et al. Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am Coll Cardiol. 2017;70:2893\u2013905.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1001_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Bertram Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"Bertram Pitt","year":"2005","unstructured":"Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425\u201331.","journal-title":"Journal of the American College of Cardiology"},{"key":"1001_CR34","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Zannad F, McMurray JJV, Krum H, Van Veldhuisen DJ, Shi H, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598\u2013603.","journal-title":"J Am Coll Cardiol"},{"key":"1001_CR35","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. Circulation. 2019;140:e125\u201351.","journal-title":"Circulation"},{"key":"1001_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1001_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"Gian Paolo Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62\u20139.","journal-title":"Hypertension"},{"key":"1001_CR38","doi-asserted-by":"crossref","unstructured":"Neefs J, van den Berg NWE, Limpens J, Berger WR, Boekholdt SM, Sanders P, et al. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;231:155\u201361.","DOI":"10.1016\/j.ijcard.2016.12.029"},{"key":"1001_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/europace\/euv366","volume":"18","author":"T Liu","year":"2016","unstructured":"Liu T, Korantzopoulos P, Shao Q, Zhang Z, Letsas KP, Li G. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Europace. 2016;18:672\u20138.","journal-title":"Europace"},{"issue":"4","key":"1001_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","volume":"71","author":"Gian Paolo Rossi","year":"2018","unstructured":"Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension. 2018;71:585\u201391.This is the largest prospective study with the longest follow-up showing a decrease of incident AF with adrenalectomy.","journal-title":"Hypertension"},{"key":"1001_CR41","doi-asserted-by":"crossref","unstructured":"Seccia TM, Letizia C, Muiesan ML, Lerco S, Cesari M, Bisogni V, et al. Atrial fiibrillation as presenting sign of primary aldosteronism: results of the PAPPHY Study. J Hypertens. 2020;in press.","DOI":"10.1097\/HJH.0000000000002250"},{"issue":"3","key":"1001_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/jhh.2012.21","volume":"27","author":"G P Rossi","year":"2012","unstructured":"Rossi GP, Seccia TM, Gallina V, Muiesan ML, Leoni L, Pengo M, et al. Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY study): rationale and study design. J Hum Hypertens. 2013;27:158\u201363.","journal-title":"Journal of Human Hypertension"},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1161\/HYPERTENSIONAHA.116.08956","volume":"69","author":"TM Seccia","year":"2017","unstructured":"Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial hypertension, atrial fibrillation, and hyperaldosteronism: the triple trouble. Hypertension. 2017;69:545\u201350.","journal-title":"Hypertension"},{"key":"1001_CR44","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0002-9149(01)01905-1","volume":"88","author":"A Goette","year":"2001","unstructured":"Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88:906\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1001_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000095671","volume":"108","author":"Ulrik Dixen","year":"2006","unstructured":"Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, et al. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology. 2007;108:35\u20139.","journal-title":"Cardiology"},{"key":"1001_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1540-8159.2009.02673.x","volume":"33","author":"B Wozakowska-Kaplon","year":"2010","unstructured":"Wozakowska-Kaplon B, Bartkowiak R, Janiszewska G. A decrease in serum aldosterone level is associated with maintenance of sinus rhythm after successful cardioversion of atrial fibrillation. Pacing Clin Electrophysiol. 2010;33:561\u20135.","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-1001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-1001-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-1001-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:35:08Z","timestamp":1605573308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-1001-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-1001-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"18 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"94"}}